RSS Search

News  Feeds  Tags  Search Shortcuts

FeedsFarm.com > Sustained Response at Month 12 for Transgene's TG 4001 in HPV-Induced Precancerous Lesions of the Cervix and Next Clinical Development Steps

Sustained Response at Month 12 for Transgene's TG 4001 in HPV-Induced Precancerous Lesions of the Cervix and Next Clinical Development Steps

13th Nov 2006, 22:41 GMT

Transgene SA announces updated data of the completed Phase II trial and development plans going forward for TG 4001, Transgene's therapeutic HPV vaccine for treating precancerous lesions of the cervix.

View full story at www.myhealthcarenews.com

Sustained Response at Month 12 for Transgene's TG 4001 in HPV-Induced Precancerous Lesions of the Cervix and Next Clinical Development Steps related news:

Latest news from Surgery News from StratCenter.com: